CDK4 and breast cancer: In summary, results from the PALOMA‐3, MONARCH‐2, and MONALEESA‐3 trials have consistently proven that the combination of CDK4/6 inhibitors with fulvestrant to be efficient in improving PFS in resistant patients with relapse patients after first‐line endocrine therapy in advanced BC.